X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (708) 708
humans (672) 672
cardiac & cardiovascular systems (596) 596
male (545) 545
female (543) 543
middle aged (487) 487
aged (474) 474
abridged index medicus (354) 354
risk factors (310) 310
mortality (261) 261
treatment outcome (243) 243
heart attacks (213) 213
cardiovascular (202) 202
acute coronary syndromes (194) 194
myocardial infarction (181) 181
clopidogrel (159) 159
percutaneous coronary intervention (158) 158
care and treatment (156) 156
prospective studies (150) 150
registries (149) 149
time factors (149) 149
cardiovascular disease (147) 147
peripheral vascular disease (139) 139
stroke (138) 138
coronary heart disease (134) 134
follow-up studies (131) 131
heart attack (126) 126
myocardial-infarction (123) 123
cardiac patients (117) 117
acute myocardial-infarction (114) 114
management (113) 113
aspirin (111) 111
medicin och hälsovetenskap (111) 111
myocardial infarction - mortality (111) 111
myocardial infarction - therapy (111) 111
medical and health sciences (110) 110
platelet aggregation inhibitors - therapeutic use (110) 110
prognosis (109) 109
cardiology (107) 107
drug therapy (107) 107
thrombosis (106) 106
patient outcomes (105) 105
medicine, general & internal (104) 104
risk assessment (104) 104
electrocardiography (101) 101
angioplasty (98) 98
coronary vessels (98) 98
internal medicine (97) 97
outcomes (96) 96
risk (95) 95
stents (95) 95
aged, 80 and over (94) 94
cardiovascular diseases (93) 93
double-blind method (92) 92
ticlopidine - analogs & derivatives (91) 91
hemorrhage - chemically induced (88) 88
drug therapy, combination (85) 85
acute coronary syndrome (84) 84
therapy (84) 84
patients (83) 83
platelet aggregation inhibitors - administration & dosage (83) 83
coronary artery disease (81) 81
prevention (81) 81
adult (78) 78
clinical trials (78) 78
diabetes (78) 78
research (78) 78
analysis (77) 77
ticagrelor (77) 77
clinical medicine (76) 76
ischemia (76) 76
transluminal angioplasty (74) 74
guidelines (72) 72
klinisk medicin (70) 70
platelet aggregation inhibitors - adverse effects (69) 69
kaplan-meier estimate (68) 68
kardiologi (68) 68
intervention (67) 67
cardiac and cardiovascular systems (66) 66
heart failure (66) 66
prevalence (64) 64
usage (64) 64
bleeding (62) 62
coronary angiography (62) 62
cardiology and cardiovascular medicine (61) 61
events (61) 61
acute coronary syndrome - drug therapy (60) 60
adenosine - analogs & derivatives (60) 60
atherosclerosis (59) 59
health aspects (59) 59
myocardial infarction - drug therapy (59) 59
secondary prevention (59) 59
studies (59) 59
trial (59) 59
anticoagulants (58) 58
medical research (58) 58
myocardial infarction - diagnosis (58) 58
outpatients (58) 58
metaanalysis (57) 57
angioplasty, balloon, coronary (56) 56
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1109) 1109
French (9) 9
Spanish (7) 7
Polish (3) 3
Italian (2) 2
German (1) 1
Portuguese (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


European heart journal, ISSN 0195-668X, 03/2019, Volume 40, Issue 15, pp. 1211 - 1213
Journal Article
Circulation, ISSN 0009-7322, 11/2018, Volume 138, Issue Suppl_1 Suppl 1, pp. A16658 - A16658
IntroductionLong-term treatment with ticagrelor 60 mg added to ASA reduces ischemic risk but increases bleeding in patients with prior MI.HypothesisClinical... 
Journal Article
European Heart Journal, ISSN 0195-668X, 08/2012, Volume 33, Issue 15, pp. 1878 - 1885
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2014, Volume 371, Issue 23, pp. 2155 - 2166
Patients who had received a drug-eluting stent and then dual antiplatelet therapy for 12 months were randomly assigned to 18 more months of therapy or aspirin... 
TRIALS | MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | MULTICENTER | CLOPIDOGREL | TICAGRELOR | THROMBOSIS | RATIONALE | PREVENTION | ASPIRIN | CLINICAL-OUTCOMES | Piperazines - administration & dosage | Prasugrel Hydrochloride | Thiophenes - adverse effects | Humans | Middle Aged | Male | Thiophenes - administration & dosage | Aspirin - administration & dosage | Incidence | Time Factors | Aspirin - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Female | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Drug Therapy, Combination | Myocardial Ischemia - epidemiology | Platelet Aggregation Inhibitors - adverse effects | Drug-Eluting Stents | Drug Administration Schedule | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Myocardial Ischemia - therapy | Aged | Hemorrhage - chemically induced | Aggregation | Treatment outcome | Care and treatment | Usage | Blood platelets | Analysis | Drug-eluting stents | Dosage and administration | Cardiovascular diseases | Thrombosis | Health aspects | Blood clot | Myocardial infarction | Cerebral infarction | Aspirin | Stroke | Drug delivery | Patients | Bleeding | Clinical outcomes | Cerebrovascular system | Coronary vessels | Implants | Clopidogrel | Drug therapy | Stents | Index Medicus | Abridged Index Medicus
Journal Article
by White, Harvey D and Held, Claes and Stewart, Ralph and Tarka, Elizabeth and Brown, Rebekkah and Davies, Richard Y and Budaj, Anzej and Harrington, Robert A and Steg, P. Gabriel and Ardissino, Diego and Armstrong, Paul W and Avezum, Alvaro and Aylward, Philip E and Bryce, Alfonso and Chen, Hong and Chen, Ming-Fong and Corbalan, Ramon and Dalby, Anthony J and Danchin, Nicolas and de Winter, Robbert J and Denchev, Stefan and Diaz, Rafael and Elisaf, Moses and Flather, Marcus D and Goudev, Assen R and Granger, Christopher B and Grinfeld, Liliana and Hochman, Judith S and Husted, Steen and Kim, Hyo-Soo and Koenig, Wolfgang and Linhart, Ales and Lonn, Eva and López-Sendón, José and Manolis, Athanasios J and Mohler, Emile R and Nicolau, José C and Pais, Prem and Parkhomenko, Alexander and Pedersen, Terje R and Pella, Daniel and Ramos-Corrales, Marco A and Ruda, Mikhail and Sereg, Mátyás and Siddique, Saulat and Sinnaeve, Peter and Smith, Peter and Sritara, Piyamitr and Swart, Henk P and Sy, Rody G and Teramoto, Tamio and Tse, Hung-Fat and Watson, David and Weaver, W. Douglas and Weiss, Robert and Viigimaa, Margus and Vinereanu, gos and Zhu, Junren and Cannon, Christopher P and Wallentin, Lars and Steg, Ph Gabriel and Bucan, Olga and Elfström, Charlotta and Hegg, Lisa and Jarosz, Marie and Krug-Gourley, Sue and Rudman, Jerry and Collins, Rory and Anderson, Jeffrey and DeMets, David and Ganz, Peter and Sandercock, Peter and Weber, Michael and Fisher, Marian and Buhr, Kevin and Diegel, Scott and Schultz, Melissa and Mahaffey, Kenneth W and Alexander, John H and Al-Khatib, Sana and Baron, Tomasz and Bergström, Olle and Bushnell, Cheryl and Christersson, Christina and Eggers, Kai and Fredlund, Bengt-Olov and Hagström, Emil and Hijazi, Ziad and Örndahl, Lovisa Holm and James, Stefan K and Jernberg, Tomas and Johnston, Nina and Lopez, Renato D and Mehta, Rajena H and Newby, Kristin L and Nordmark, Örjan and Oldgren, Jonas and Roe, Matthew T and Saldéen, Katarina and Stenborg, Anna and ... and The STABILITY Investigators and STABILITY Investigators and Medicinska fakulteten and Medicinska och farmaceutiska vetenskapsområdet and Kardiologi and Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm and Uppsala universitet and Institutionen för medicinska vetenskaper and Uppsala kliniska forskningscentrum (UCR)
The New England Journal of Medicine, ISSN 0028-4793, 05/2014, Volume 370, Issue 18, pp. 1702 - 1711
Darapladib, an oral inhibitor of lipoprotein-associated phospholipase A2, was compared with placebo in 15,828 patients with stable coronary heart disease.... 
TRIAL | LIPOPROTEIN | MEDICINE, GENERAL & INTERNAL | THERAPY | ACTIVATING-FACTOR ACETYLHYDROLASE | OXIDIZED LDL | RISK | PHOSPHOLIPASE A | ATHEROSCLEROTIC PLAQUE | INHIBITOR | CLINICAL-OUTCOMES | Stroke - prevention & control | Double-Blind Method | Follow-Up Studies | Oximes - adverse effects | Phospholipase A2 Inhibitors - administration & dosage | Humans | Middle Aged | Kaplan-Meier Estimate | Oximes - administration & dosage | Male | Coronary Artery Disease - drug therapy | Coronary Disease - mortality | Phospholipase A2 Inhibitors - adverse effects | Benzaldehydes - adverse effects | Benzaldehydes - administration & dosage | Coronary Artery Disease - complications | Treatment Failure | Coronary Disease - drug therapy | Female | Aged | Myocardial Infarction - prevention & control | Prevention | Care and treatment | Ischemia | Dosage and administration | Research | Coronary heart disease | Cardiovascular agents | Myocardial infarction | Cerebral infarction | Phospholipase A2 | Clinical trials | Myocardial ischemia | Cardiovascular disease | Angina | Preventive medicine | Coronary artery disease | Phospholipase | Arteriosclerosis | Death | Plasma levels | Drug therapy | Heart diseases | Plaques | Index Medicus | Abridged Index Medicus | Malalties cardiovasculars | Infart de miocardi | Malalties coronàries | Assaigs clínics de medicaments | Cardiovascular diseases | Drug testing | Coronary diseases | Clinical Medicine | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9749, pp. 1320 - 1328
Summary Background In the PLATO trial of ticagrelor versus clopidogrel for treatment of acute coronary syndromes, ticagrelor reduced the composite outcome of... 
Internal Medicine | ALLELE | MEDICINE, GENERAL & INTERNAL | INHIBITION | ANTAGONIST | PLATELET-AGGREGATION | STENT THROMBOSIS | OF-FUNCTION POLYMORPHISM | P-GLYCOPROTEIN EXPRESSION | PRASUGREL | PHARMACOGENETICS | TREATED PATIENTS | Ticlopidine - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Aryl Hydrocarbon Hydroxylases - genetics | Male | Adenosine - adverse effects | Adenosine - therapeutic use | Ticlopidine - adverse effects | Female | Platelet Aggregation Inhibitors - therapeutic use | Platelet Aggregation Inhibitors - adverse effects | Cardiovascular Diseases - etiology | Pharmacogenetics | Genotype | Ticlopidine - analogs & derivatives | Randomized Controlled Trials as Topic | Acute Coronary Syndrome - drug therapy | Phenotype | ATP-Binding Cassette, Sub-Family B, Member 1 - genetics | Cytochrome P-450 CYP2C19 | Adenosine - analogs & derivatives | ATP Binding Cassette Transporter, Sub-Family B | Aged | Polymorphism, Single Nucleotide | Acute Coronary Syndrome - genetics | Care and treatment | Patient outcomes | Physiological aspects | Clopidogrel | Dosage and administration | Single nucleotide polymorphisms | Health aspects | Coronary heart disease | Studies | Heart attacks | Statistical analysis | Metabolites | Genetics | Drug therapy | Gene expression | Acute coronary syndromes | Myocardial infarction | Stroke | Single-nucleotide polymorphism | Arteries | Bleeding | Index Medicus | Abridged Index Medicus | Medical and Health Sciences | MEDICINE | Medicin och hälsovetenskap | MEDICIN
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 10/2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics | Index Medicus | Abridged Index Medicus | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article